[{"from": "human", "value": "Provide a description of this molecule. [C][N][Branch1][C][C][C][Branch2][Ring2][Ring1][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][C][=C][Branch1][=Branch1][C][C][O][Ring1][Branch2][C][=C][Branch1][Ring2][N][Ring1][Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][#Branch1][F][C][=C][C][=C][C][=C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is an orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, with potential anti-nociceptive activity. Upon oral administration, cebranopadol binds to NOP and the mu, delta and kappa opioid receptors, which enhances NOP- and opioid receptor-mediated signaling, interferes with the sensation of pain and results in an analgesic effect. NOP, a member of the opioid receptor family, and its endogenous ligand nociceptin play key roles in the regulation of various brain activities including pain, and some inflammatory and immune responses."}]